Objectives: The emergence of fluconazole resistance in Candida parapsilosis healthcare-associated infections has recently been increasingly reported. Antifungal susceptibility profiles and mechanisms of fluconazole resistance in C. parapsilosis (n " 199) from nine hospitals in India collected over a period of 3 years were studied. Further, clonal transmission of fluconazole-resistant isolates in different hospitals was investigated.
Introduction
Candida parapsilosis infection is increasingly reported among hospitalized patients and, particularly in certain geographical areas, this yeast is the main pathogen causing candidaemia. [1] [2] [3] [4] Among the C. parapsilosis species complex, C. parapsilosis (sensu stricto) is the most common non-albicans Candida (NAC) species isolated from bloodstream infections (BSIs) in Spain, Italy and many countries in Latin America. [5] [6] [7] [8] [9] [10] Notably, 12%-17% of cases of candidaemia in the USA are caused by C. parapsilosis, which accounts for the second or third most common cause of candidaemia. multicentre laboratory-based survey of candidaemia, species distribution and antifungal susceptibility in 11 public and .85 privatesector hospitals in South Africa showed that C. parapsilosis was the dominant species. The most significant finding was that of 531 C. parapsilosis isolates investigated, only 199 (37%) were susceptible to fluconazole and more than half were resistant to fluconazole. 19 Certainly, C. parapsilosis has emerged as an important and potentially antifungal-resistant nosocomial pathogen that has unique ability to grow on inanimate objects and surfaces, and spread by healthcare workers via hand carriage. [20] [21] [22] The emergence of fluconazole-resistant strains in healthcare settings poses a serious threat owing to cross-infections among hospitalized patients. Thus, in-country surveillance studies, to monitor antifungal susceptibility trends, are useful to determine appropriate treatment strategies. However, so far, large multicentre studies monitoring azole resistance and investigating the underlying molecular mechanism in azole-resistant C. parapsilosis isolates in India are lacking. In the present study, we evaluated azole resistance in clinical isolates of C. parapsilosis sensu stricto collected from nine hospitals in India during a 3 year surveillance study of candidiasis, in which all yeast isolates were collected from 2015 to 2017. 23 The azole target ERG11 gene was screened, and the significance of the novel A428G mutation that resulted in the non-synonymous amino acid substitution K143R in fluconazole-non-susceptible C. parapsilosis isolates was determined by direct transformation into Saccharomyces cerevisiae through gap-repair cloning. Additionally, we performed microsatellite analysis to determine the clonal lineage of fluconazole-non-susceptible C. parapsilosis strains circulating among different hospitals in India.
Materials and methods

Fungal isolates and identification
A total of 199 clinical C. parapsilosis sensu stricto isolates collected from nine tertiary care hospitals in Delhi, the adjoining National Capital Region (NCR) in the North and a single centre in South India, Kochi, over a period of 3 years (2015-17) were analysed. The isolates were mainly from patients with candidaemia (blood n " 126; bone marrow n " 1) and other invasive Candida infections (tissue n " 10; pus n " 1). Also, isolates from nails (n " 23), urine (n " 23), respiratory specimens (n " 10), sino-nasal specimens (n " 3), skin swab (n " 1) and corneal scraping (n " 1) were included. All isolates were screened on CHROMagar TM Candida medium and were cultured on Sabouraud dextrose agar (SDA) for 24 h at 37 C. They were identified by MALDI-TOF MS (Bruker Biotyper OC version 3.1, Daltonics, Bremen, Germany) using the ethanol-formic acid extraction method and yielded a score value .2.
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In vitro antifungal susceptibility testing
Antifungal susceptibility testing (AFST) was performed by using the CLSI broth microdilution (CLSI-BMD) method, following M27-A3/S4. 25, 26 Antifungals tested were fluconazole, itraconazole, voriconazole, posaconazole, isavuconazole, amphotericin B and 5-flucytosine. The drug dilution range tested was 0.125-64 mg/L for fluconazole and 5-flucytosine, 0.03-16 mg/L for itraconazole, voriconazole and amphotericin B, and 0.015-8 mg/L for isavuconazole and posaconazole. Candida krusei ATCC 6258 and C. parapsilosis ATCC 22019 were used as quality control strains. The modal MICs, geometric mean (GM) MICs with 95% CIs, MIC 50 , MIC 90 , medians and ranges were calculated using Prism version 6.00 (GraphPad Software). In accordance with the CLSI M27-S4, resistance to fluconazole was defined as MIC 8 mg/L and susceptible dose-dependent (SDD) as an MIC of 4 mg/L. For voriconazole, an MIC of 1 mg/L was defined as resistant and an MIC of 0.25-0.5 mg/L as intermediate.
ERG11 gene amplification and sequencing
All fluconazole-non-susceptible C. parapsilosis isolates (55 resistant isolates, 9 SDD isolates) and 19 randomly selected fluconazole-susceptible isolates were subjected to ERG11 gene sequencing. Genomic DNA was extracted using the chloroform-isoamyl alcohol method as described by Xu et al. 27 The amplification primers for the azole target ERG11 gene of C. parapsilosis sensu stricto were selected as described by Grossman et al. 28 PCR was carried out in a 50 lL reaction volume and the conditions included initial denaturation for 5 min at 95 C followed by 34 cycles of 30 s at 95 C, 30 s at 58 C and 180 s at 72 C. DNA sequencing was performed using the PCR primers at 2.5 mM concentration. All sequencing reactions were carried out in a 10 lL reaction volume using BigDye Terminator Kit v3.1 (Applied Biosystems) according to the manufacturer's recommendations and analysed on an ABI3130xL Genetic Analyzer (Applied Biosystems). Consensus sequences were made using BioEdit software (version 7.0.5.3) and were aligned with the ERG11 gene of reference C. parapsilosis ATCC 22019 (GenBank accession number: GQ302972.1)
Gap-repair cloning of the ERG11 gene carrying K143R and Y132F amino acid substitution alleles in S. cerevisiae
The effect on fluconazole susceptibility of the novel K143R amino acid substitution identified in the present study and the previously described Y132F amino acid substitution was determined by expressing C. parapsilosis ERG11 alleles in S. cerevisiae strain BY4741 (MATa his3D1 leu2DD met15DD ura3DD) using gap-repair cloning methodology. S. cerevisiae strain BY4741 is auxotrophic for uracil. A low-copy plasmid, pRS416-Gal4-dCas9-VP64 (a gift from Ronald Davis, Addgene plasmid #71128), was used for the gap-repair cloning experiment. 29 The plasmid pRS416 was used for point mutation constructs carrying K143R and Y132F alleles. Escherichia coli DH5a was used for propagation of the plasmid. The C. parapsilosis ERG11 allele including the promoter region and gap-repair cloning primers that contain overhang regions homologous to each side of the SmaI restriction site in the pRS416 plasmid were amplified (Table S1 , available as Supplementary data at JAC Online). Briefly, the PCR product of gap-repair cloning primers was purified using the QIAquick PCR Purification Kit (Qiagen, Milan, Italy) according to the manufacturer's guidelines. The plasmid DNA from E. coli was isolated as described previously 30 followed by overnight digestion of pRS416 plasmid DNA with the restriction endonuclease SmaI (Roche, Mannheim, Germany) to linearize the plasmid for gap repair. After digestion, the enzyme was inactivated at 65 C for 20 min. The linearized vector was analysed by agarose gel electrophoresis to confirm the digestion. The linear DNA was dephosphorylated with shrimp alkaline phosphatase (SAP) to prevent recirculation of the plasmid. S. cerevisiae competent cells were prepared using the protocol of the Frozen EZ Yeast transformation kit (Zymo Research, Irvine, CA, USA). Next, linearized pRS416 and C. parapsilosis ERG11 purified PCR product (CpaERG11-WT, CpaERG11-Y132F and CpaERG11-K143R) were co-transformed in S. cerevisiae BY4741 competent cells. Another two sets of agar plates carrying an empty (positive control) as well as a linearized plasmid (negative control) were also included in the transformation step. The transformed colonies were selected on agar plates containing medium lacking uracil (CSM-ura). Recombinant clones were distinguished by colony PCR using an upstream forward primer on the plasmid and an internal reverse primer in ERG11 (Table S1 ). The positive clones were Fluconazole-resistant clonal C. parapsilosis JAC streaked on a CSM-ura medium-containing agar plate at 30 C for 3 days and cultured overnight in liquid CSM-ura for further screening. For each transformation, multiple PCR-positive colonies were passaged on CSM-ura medium and plasmid inserts were sequenced to confirm ERG11 genotypes. MICs were determined in both nutrient-rich yeast extract-peptone-dextrose (YPD) and nutrient-limited (CSM-ura) media.
Microsatellite typing
Genomic DNA of C. parapsilosis isolates was extracted from 48-hour-old cultures with the MagNAPure 96 platform (Roche Diagnostics, Almere, The Netherlands) as described previously. 31 Two multiplex PCRs were performed to amplify three trinucleotide repeat regions in one PCR and three hexanucleotide repeat regions in the second PCR; the setup of these assays has been described previously. 32 Subsequently, the PCR products were diluted 20-200% with double-distilled H 2 O (ddH 2 O) and 1.0 lL of this dilution was added to a mixture of 0.1 lL of CC-500ROX (Promega, Leiden, The Netherlands) and 8.9 lL of ddH 2 O. Prior to data analysis, samples were boiled for 1 min at 95 C and then cooled to 4 C. Data analysis was performed on an ABI3500xL genetic analyser platform and subsequently analysed with GeneMapper software (Applied Biosystems, Palo Alto, CA, USA). Microsatellite profiles were imported into BioNumerics v6.6 (Applied Maths, Sint-Martens-Latem, Belgium), and a dendrogram was generated by treating the data as categorical values, followed by cluster analysis by the unweighted-pair group method using average linkages.
Results
Identification
C. parapsilosis sensu stricto (n " 199) isolates comprised individual bloodstream isolates originating from 127 patients with candidaemia and constituted 64% of the isolates investigated. Further, 5.5% (n " 11) of the isolates were from invasive Candida infections mainly from post-operative tissue specimens (n " 10) and pus (n " 1). The remaining 31% (n " 61) of isolates were obtained from various specimens as detailed above.
In vitro susceptibility testing
The MIC data for C. parapsilosis isolates of seven antifungals by the CLSI-BMD method are detailed in Table 1 . Remarkably, 32%
(n " 64) of C. parapsilosis isolates were non-susceptible to fluconazole; this included resistant (n " 55; MIC .4 mg/L) and SDD isolates (n " 9). The MIC distribution of fluconazole for C. parapsilosis was spread over nine dilutions (range 0.125-32 mg/L). A high fluconazole MIC 90 of 16 mg/L for C. parapsilosis isolates was recorded. The modal MIC of fluconazole was 0.5 mg/L and an additional peak at MIC 2 mg/L was noted in 12% (n " 24) of isolates followed by a truncated MIC distribution at 8 and 16 mg/L in 26 and 27 isolates, respectively. Further, 18% (n " 10/55) of fluconazoleresistant isolates had intermediate MICs (0.25-0.5 mg/L) of voriconazole. Low GM MICs were noted for the remaining azoles ( Table 1 ). The modal MICs of itraconazole, voriconazole, isavuconazole and posaconazole were 0.125, 0.03, 0.015 and 0.015 mg/L, respectively. Interestingly for 5-flucytosine, isavuconazole, amphotericin and posaconazole, modal MIC +1 two-fold dilution comprised 99% (n " 198), 95% (n " 189), 90% (n " 179) and 85% (n " 170) for C. parapsilosis strains, respectively. For itraconazole and voriconazole, 74% of isolates fell in modal MIC +1 two-fold dilution.
ERG11 mutation analysis
A total of 83 C. parapsilosis isolates including all fluconazole-nonsusceptible isolates (n " 64; 55 resistant and 9 SDD) and 19 randomly selected susceptible isolates were screened for ERG11 mutations. These selected isolates included mainly BSIs (80%), and the remaining 20% were from other specimens in 9 hospitals. The comparison of C. parapsilosis ERG11p amino acid sequences with the WT ATCC 22019 C. parapsilosis isolate (GenBank accession number: GQ302972.1) showed that 63 (76%) of 83 isolates had overall three amino acid substitutions, i.e. Y132F, K143R and R398I. Notably, 94.5% (n " 52) of fluconazole-resistant isolates had the novel K143R amino acid substitution and the remaining three resistant isolates had the previously described Y132F substitution. In the remaining nine SDD isolates (MIC 4 mg/L), eight isolates had either K143R (n " 6) or Y132F (n " 2) substitution, and a single SDD isolate was negative for either K143R or Y132F substitution. Additionally, 16 resistant, 6 SDD and 10 susceptible isolates had an R398I amino acid substitution ( Table 2) . Singh et al.
Fluconazole susceptibility of S. cerevisiae transformants carrying C. parapsilosis Y132F and K143R S. cerevisiae that expressed C. parapsilosis Y132F or K143R exhibited 16-fold less susceptibility to fluconazole than the transformants expressing the WT ERG11 or empty vector ( Table 3) . The results of AFST in both nutrient-rich (YPD) and nutrient-limited (CSM-ura) media were consistent (2-fold changes) ( Table 3) .
Microsatellite analysis
The short tandem repeat (STR) typing of 51 C. parapsilosis clinical isolates from all nine hospitals with 35 non-susceptible (27 resistant and 8 SDD) and 16 susceptible isolates demonstrated 28 genotypes. The genetic relatedness of C. parapsilosis is depicted in Figure 1 . Out of 28 genotypes, 13 were exclusively noted in nonsusceptible isolates, whereas 14 genotypes were found among susceptible isolates. Among the 13 non-susceptible genotypes, seven clusters (2 identical genotypes at all loci) comprising 29 isolates were noted. Cluster I containing six isolates was distributed in three Delhi hospitals and a single hospital in Kochi, South India. Similarly, cluster II comprising 10 identical genotypes was distributed in seven hospitals. Notably, these two large clusters of non-susceptible isolates, i.e. I and II, were highly related, differing only at one locus. The remaining five clusters (III-VII) had 2-3 isolates in each cluster which were randomly distributed in seven of nine hospitals. Interestingly, 14 out of the 16 susceptible isolates were randomly distributed in seven hospitals, with no clustering noted. Two susceptible isolates had an identical genotype in two hospitals, one in Delhi and another in Kochi, South India.
Discussion
The present study is the first comprehensive report documenting alarmingly high rates of fluconazole resistance in C. parapsilosis sensu stricto isolates in India. Overall, 32% of isolates collected during 2015-17 in the present multicentre study were not susceptible (resistant and SDD isolates) to fluconazole. Further, the study is noteworthy as it records a novel amino acid substitution, K143R, in the azole target ERG11p in 92% of fluconazole-non-susceptible C. parapsilosis isolates. This is the first report, to our knowledge, verifying the role of the novel K143R and the previously described Y132F amino acid substitutions leading to the fluconazoleresistant phenotype in C. parapsilosis isolates by transformation of ERG11 into S. cerevisiae. Until now, only the Y132F substitution in ERG11p has been reported exclusively in fluconazole-resistant C. parapsilosis isolates from Brazil, the USA, Kuwait and, more recently, South Korea. 28, [33] [34] [35] Interestingly, in the present study, both K143R and Y132F amino acid substitutions were also detected in SDD isolates of C. parapsilosis. Considering that in in vitro analysis, both the mutations conferred the fluconazole-resistant phenotype, the accuracy of CLSI SDD breakpoints of fluconazole that differ only by 2-fold dilution for fluconazole-resistant isolates (4 and 8 mg/L, respectively) warrants further investigations in in vivo models. Previously, a large-scale study analysing the ERG11 gene in 30 resistant isolates, 37 SDD isolates and 55 susceptible isolates collected from hospitals in four US cities demonstrated five SNPs in 54 isolates. Only amino acid substitution Y132F was exclusively found in 17 resistant isolates. 28 Recently, a study from Korea screened the ERG11 genes of 47 fluconazole-resistant C. parapsilosis bloodstream isolates; 63.8% had the Y132F substitution in ERG11p. 35 In contrast to the above-mentioned worldwide data that document Y132F substitution in ERG11p as the predominant fluconazole resistance mechanism in C. parapsilosis, in many centres in Delhi and a single centre in South India, the K143R amino acid substitution was the predominant single resistance mechanism in resistant isolates. Both K143R and Y132F amino acid substitutions have been previously associated with azole resistance in Candida tropicalis, Candida auris and Candida albicans. [36] [37] [38] [39] [40] [41] [42] The residues Tyr132 and Lys143 lie within the substratebinding pocket of the ERG11 protein (lanosterol 14a-demethylase) and have been shown in S. cerevisiae to interact directly with and stabilize the binding of fluconazole. As anticipated, mutation of these residues adversely affects the binding of fluconazole, resulting in reduced susceptibility. 43 Recently, Healey et al. 39 also detected elevated azole MICs in S. cerevisiae upon heterologous expression of C. auris ERG11 alleles carrying Y132F or K143R substitutions. The ERG11 gene is highly conserved among Candida species, and specific ERG11 substitutions in C. albicans, including Y132F and K143R, have been shown to exhibit reduced susceptibilities to azoles upon heterologous expression in S. cerevisiae. 41, 42, 44 In the present laboratory-based surveillance, a total of 1536 Candida isolates collected from nine hospitals in Delhi and a single centre in Kochi during 2015-17 showed the C. parapsilosis species complex (n " 296) to be the third most common species after C. tropicalis and C. auris. A prospective, nationwide, multicentre study conducted in 27 Indian ICUs during 2011-12 analysed 918 Candida isolates and documented C. parapsilosis as an important agent of candidaemia in Indian ICUs. C. parapsilosis ranked third (10.9%) in order after C. tropicalis (41.6%) and C. albicans (20.9%). 45 Although the rate of fluconazole resistance in the present study varied among seven hospitals, ranging from 12% to 76%, overall the resistance was equally distributed year-wise among hospitals. Overall, no resistance to voriconazole was observed in C. parapsilosis isolates, although 5% (n " 10) had intermediate MICs of voriconazole. No cross-resistance to other azoles, i.e. itraconazole, posaconazole and isavuconazole, was noted. This observation is in contrast to the report from South Africa wherein 44% fluconazole-resistant C. parapsilosis isolates were crossresistant to voriconazole. 19 The majority of bloodstream isolates of C. parapsilosis analysed in the present study originated equally from patients admitted to ICUs (medical and surgical ICUs; 48%) and those admitted to medical and post-operative wards (40%). Only 10% and 2% of the isolates were from oncology and haematology patients, respectively. Further, an equal distribution of fluconazole-non-susceptible isolates of C. parapsilosis was noted in ICUs (39%) and wards (37.5%). However, remarkable differences in the susceptibility to fluconazole were noted with respect to the clinical specimens investigated. Notably, 42% of bloodstream isolates were non-susceptible to fluconazole, followed by urine (26%), tissue (20%) and nail specimens (13%). Interestingly, none of the respiratory specimens yielded fluconazole-non-susceptible C. parapsilosis isolates. In the present study, only 42% of patients with the K143R substitution had antifungal exposure within 15-27 days before detection of candidaemia, whereas 22% of patients in whom C. parapsilosis isolates were identified in other specimens had antifungal exposure 30 days before isolation. Considering that .60% of our patients had no previous exposure to fluconazole, it is highly likely that fluconazole-resistant Fluconazole-resistant clonal C. parapsilosis 
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C. parapsilosis strains were acquired from hospital sources. The fact that fluconazole is the most commonly used antifungal in several hospitals in India for prophylaxis and treatment of candidaemia and other fungal infections may have led to the emergence and subsequent nosocomial transmission of fluconazole-resistant strains. C. parapsilosis is a commensal of human skin that can be transmitted horizontally via contaminated external sources and the hands of healthcare workers. [46] [47] [48] The possible sources of infection in the present study could be related to the well-known risk factors in a hospital environment, including contaminated medical devices and environmental surfaces, and subsequent transmission amongst patients could be attributed to less stringent adherence to infection control practices. Molecular typing of fluconazoleresistant strains suggested that resistant clonal strains harbouring K143R mutations were circulating in seven of the eight hospitals. Further, two major resistant clonal genotypes (cluster I and cluster II) comprising 16 C. parapsilosis isolates differed from each other in only one locus, suggesting clonal expansion of non-susceptible isolates in hospitals. These fluconazole-resistant clonal strains very probably remain undetected and their spread by nosocomial transmission is challenging to curtail. Interestingly, in the present study Fluconazole-resistant clonal C. parapsilosis JAC in contrast to the fluconazole-resistant clonal strains harbouring K143R mutations, in susceptible isolates without ERG11 SNPs, no hospital specificity was detected. The presence of clusters of identical genotypes infecting different patients suggests patient-to-patient transmission or via a common source. Many of the clustered isolates were spread over multiple hospitals, suggesting a possible transmission across hospitals through shared patients. Nevertheless, this assumption remains purely speculative as information regarding patient sharing among different hospitals was not available. The other aspect, that strains harbouring K143R and Y132F mutations could possibly persist in the hospital environment, as previously shown for C. auris, and are subsequently transmitted, causing healthcaressociated infections, also warrants further studies. Recently, a study from Korea demonstrated that fluconazole-resistant C. parapsilosis isolates harbouring Y132F persist in hospitals. 35 Perhaps ERG11 SNPs in clonal isolates may enable those strains to be particularly resilient and result in cross-infection in several patients. 28 Also, clusters of C. parapsilosis genotypes causing candidaemia differed between hospitals, suggesting differences in strain transmission possibly related to differences in healthcare practices, or the type of patients admitted to each hospital. Occasionally, the same genotypes were found in patients admitted to different hospitals located in the same city. It is well known that exogenous strains of C. albicans, C. parapsilosis and C. auris can infect patients admitted to hospital and cause outbreaks of candidaemia. [46] [47] [48] [49] Previously, genotype clustering has been reported in hospitals located in the same country. [50] [51] [52] However, the transmission of fluconazoleresistant clonal strains harbouring mutations in the ERG11 gene in C. parapsilosis is limited. 28, 36 Finally, antifungal resistance is an emerging problem worldwide. Considering that fluconazole remains the standard initial treatment for patients with invasive candidiasis owing to its low cost and safety profile, the emergence of fluconazole resistance in C. parapsilosis sensu stricto strains in India is concerning. The unusual finding of a dominant K143R substitution in ERG11p in fluconazole-resistant C. parapsilosis sensu stricto strains in several hospitals in India warrants further studies on its persistence and transmission behaviour in hospital settings. 
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